What is Peptide T?

A short synthetic peptide studied in the 1980s and 1990s for HIV-related conditions; its research form is D-Ala-Peptide-T-amide.

Peptide T in the library · · Human Trials · What are peptides?

5 registered trials · 16 indexed papers · 20 human / 8 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A short synthetic peptide studied in the 1980s and 1990s for HIV-related conditions; its research form is D-Ala-Peptide-T-amide.

Type: Synthetic peptide.

Definition (National Library of Medicine)

“N-(N-(N(2)-(N-(N-(N-(n-d-Alanyl L-seryl)-L-threonyl)-L-threonyl) L-threonyl)-L-asparaginyl)-L-tyrosyl) L-threonine. Octapeptide sharing sequence homology with HIV envelope protein gp120. The core pentapeptide sequence, TTNYT, consisting of amino acids 4-8 in peptide T, is the HIV envelope sequence required for attachment to the cd4 receptor.”

MeSH: Peptide T

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Peptide T is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (5)

Trial	Phase	Status	Year	Enrolled
Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)	Phase 2	unknown	2009	40
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS		completed	2001
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.	Phase 2	completed	1990	215
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.	Phase 1	completed	1988	30
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).	Phase 1	completed	1988	6

Peer-reviewed studies (16)

Paper	Authors	Journal	Year	Type
Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment	Goodkin K et al.	Journal of neurovirology	2006	Randomized Controlled Trial
Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)	Polianova MT et al.	Peptides	2003	Clinical Trial
Anti-chemotactic activities of peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis	Raychaudhuri SK et al.	International journal of immunopharmacology	1998	Clinical Trial
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment	Heseltine PN et al.	Archives of neurology	1998	Randomized Controlled Trial
Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T	Kosten TR et al.	The American journal of drug and alcohol abuse	1997	Controlled Clinical Trial
Analyses of peptide T efficacy on neuropsychological performance		AIDS patient care and STDs	1996	Randomized Controlled Trial
Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group	Simpson DM et al.	Neurology	1996	Randomized Controlled Trial
Peptide T: negative trial result	James JS	AIDS treatment news	1995	Randomized Controlled Trial
Peptide T		GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies	1995	Clinical Trial
Peptide T for cognitive impairment	Smart T	GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies	1995	Controlled Clinical Trial
Neuropsychological effects of AIDS studied		Journal of psychosocial nursing and mental health services	1991	Clinical Trial
Peptide T improves psoriasis when infused into lesions in nanogram amounts	Farber EM et al.	Journal of the American Academy of Dermatology	1991	Controlled Clinical Trial
Results of extended peptide T administration in AIDS and ARC patients	Bridge TP et al.	Psychopharmacology bulletin	1991	Controlled Clinical Trial
Peptide T a new treatment for psoriasis? A study of nine patients	Marcusson JA et al.	Acta dermato-venereologica	1991	Clinical Trial
Clinical trials planned for new AIDS drug	Kolata G	Science (New York, N.Y.)	1987	Clinical Trial
AIDS drug trials to start amid controversy	Newmark P	Nature	1987	Clinical Trial

More cited research

Thymosin alpha 1: amino acid homology with peptide T from the human immunodeficiency virus envelope (1987, human observational)
VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death (1999, animal)
Peptide T does not affect induction of pineal N-acetyltransferase by vasoactive intestinal peptide (1989, animal)
HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates (1993, animal)
Nonadrenergic noncholinergic neurotransmitter of feline trachealis: VIP or nitric oxide? (1993, animal)

Conditions researched

Related compounds

FAQ

What is Peptide T?

A short synthetic peptide studied in the 1980s and 1990s for HIV-related conditions; its research form is D-Ala-Peptide-T-amide.

How many registered human trials study Peptide T?

The PeptideWhiz trial index lists 5 registered trials for Peptide T, the most recent from 2009.

How much published research exists on Peptide T?

The PeptideWhiz paper index links 16 PubMed papers to Peptide T; by study type, 20 human and 8 animal studies.

Which conditions is Peptide T researched for?

Cognition, focus & brain performance, Dementia, Alzheimer's & cognitive decline, Immune system (general), Neuropathy and CRPS, Psoriasis and psoriatic arthritis.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research